CTLA4 and non-small cell lung carcinoma: For the EGFR group, the proportions of ALK-rearranged NSCLC were 52.50% (CTLA4+/CD8+), 7.50% (CTLA4-/CD8-), 20.00% (CTLA4+/CD8-), and 20.00% (CTLA4-/CD8+) (Figure 6B).